LB Pharmaceuticals (LBRX) Stock Price, News & Analysis

Company Overview

LB Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious neuropsychiatric disorders. The company’s lead product candidate, LB-102, is a long-acting injectable antipsychotic being developed for the treatment of schizophrenia.

LB-102 is designed to provide sustained delivery of its active pharmaceutical ingredient and potentially support adherence compared with daily oral therapies. LB Pharmaceuticals is evaluating the candidate through clinical development intended to assess its safety, tolerability, pharmacokinetics and effectiveness in people with schizophrenia.

The company’s activities are centered on advancing its pipeline through clinical trials and regulatory development. Publicly available information about LB Pharmaceuticals’ broader product portfolio, geographic operations and leadership is limited.

Key Stats

• Today's Range: $44.55 to $45.72
• 50-Day Range: $30.59 to $49.48
• 52-Week Range: $13.36 to $50.16
• Volume: 242,770 shs
• Average Volume: 252,805 shs
• Market Capitalization: $1.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.63
• Consensus Rating: Moderate Buy

LB Pharmaceuticals Stock Analysis - MarketRank™

LB Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat, and ranked 726th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LB Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

LB Pharmaceuticals has a consensus price target of $49.63, representing about 10.7% upside from its current price of $44.84.

Amount of Analyst Coverage

LB Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for LB Pharmaceuticals are expected to grow in the coming year, from ($5.78) to ($5.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LB Pharmaceuticals is -13.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LB Pharmaceuticals is -13.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LB Pharmaceuticals has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.37% of the float of LB Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

LB Pharmaceuticals has a short interest ratio ("days to cover") of 19.89, which indicates bearish sentiment.

Change versus previous month

Short interest in LB Pharmaceuticals has recently increased by 2.37%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LB Pharmaceuticals does not currently pay a dividend.

Dividend Growth

LB Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.26

News Sentiment

LB Pharmaceuticals has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for LB Pharmaceuticals this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added LB Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LB Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.80% of the stock of LB Pharmaceuticals is held by insiders.

Percentage Held by Institutions

LB Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/15/2026
• TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit: 9/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LBRX
• CIK: 1691082
• Web: lbpharma.us
• Phone: (917) 450-6581
• Fax: N/A
• Employees: 27
• Year Founded: 2015

Price Target and Rating

• Average Price Target for LB Pharmaceuticals: $49.63
• High Price Target: $78.00
• Low Price Target: $34.00
• Potential Upside/Downside: +10.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -25.92%
• Return on Assets: -24.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.08
• Quick Ratio: 15.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.91 per share
• Price / Book: 3.76

Miscellaneous

• Outstanding Shares: 32,259,000
• Free Float: 30,388,000
• Market Cap: $1.45 billion
• Optionable: N/A
• Beta: N/A